Vaccination in Patients with Inflammatory Bowel Diseases
Standard
Vaccination in Patients with Inflammatory Bowel Diseases. / Manser, Christine N; Maillard, Michel H; Rogler, Gerhard; Schreiner, Philipp; Rieder, Florian; Bühler, Silja; Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology.
in: DIGESTION, Jahrgang 101 Suppl 1, 2020, S. 58-68.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Vaccination in Patients with Inflammatory Bowel Diseases
AU - Manser, Christine N
AU - Maillard, Michel H
AU - Rogler, Gerhard
AU - Schreiner, Philipp
AU - Rieder, Florian
AU - Bühler, Silja
AU - Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology
N1 - © 2020 S. Karger AG, Basel.
PY - 2020
Y1 - 2020
N2 - During the course of disease, a majority of inflammatory bowel disease (IBD) patients requires long-term immunosuppressive therapy with either immunomodulatory agents, biologics, or newer immunosuppressive therapies such as Vedolizumab, a selective α4β7 inhibitor, Ustekinumab, an IL 12/23 p40 inhibitor, or the Janus kinase inhibitor Tofacitinib. Due to this, they are at increased risk for infectious diseases, many of which are possible to prevent by vaccination. This review focuses on recommended vaccinations in IBD patients and stresses special issues which have to be paid attention to. The aim of the review is to increase gastroenterologists' awareness of the importance of vaccination and to stress why especially the gastroenterologist should assess the vaccination status of the patient and initiate vaccination as soon as diagnosis is established.
AB - During the course of disease, a majority of inflammatory bowel disease (IBD) patients requires long-term immunosuppressive therapy with either immunomodulatory agents, biologics, or newer immunosuppressive therapies such as Vedolizumab, a selective α4β7 inhibitor, Ustekinumab, an IL 12/23 p40 inhibitor, or the Janus kinase inhibitor Tofacitinib. Due to this, they are at increased risk for infectious diseases, many of which are possible to prevent by vaccination. This review focuses on recommended vaccinations in IBD patients and stresses special issues which have to be paid attention to. The aim of the review is to increase gastroenterologists' awareness of the importance of vaccination and to stress why especially the gastroenterologist should assess the vaccination status of the patient and initiate vaccination as soon as diagnosis is established.
U2 - 10.1159/000503253
DO - 10.1159/000503253
M3 - SCORING: Review article
C2 - 31968344
VL - 101 Suppl 1
SP - 58
EP - 68
JO - DIGESTION
JF - DIGESTION
SN - 0012-2823
ER -
